Idasanutlin | p53-MDM2 inhibitor

CAS:1229705-06-9

Catalog Number:10-4174

Idasanutlin (1229705-06-9) is a potent (IC50 = 6 nM) and selective inhibitor of MDM2, the primary negative regulator 

of p53.1 It blocks the p53-MDM2 interaction activating the p53 pathway leading to cell cycle arrest and apoptosis.  

Idasanutlin has displayed efficacy in the treatment of multiple cancers alone and in combination with other chemotherapeutics.2-6

Activity:p53-MDM2 inhibitor

Chemical Names:

4-[[(2R,3S,4R,5S)-3-(3-Chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid

Alternate Name:RG7388

Molecular Weight:616.49

Molecular Formula:C31H29Cl2F2N3O4

Solubility:Soluble in DMSO (>25 mg/ml)

Physical Properties:White solid

Purity:>98% HPLC

NMR: (Conforms)

Storage Temperature:-20°C

Stability:Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.

Shipping Code:RT

References/Citations:

Ding et al. (2013), Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development; J. Med. Chem. 56 5979

Cui et al. (2020), Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the 

PI3K/AKT/mTOR pathway; Biochem. Biophys. Res. Commun. 533 665

Vernooij et al. (2021), High-Throughput Screening Identifies Idasanutlin as a Resinsitizing Drug for Venetoclax-Resistant Neuroblastoma Cells; Mol. Cancer Ther. 20 1161

Wang et al. (2022), Genome-wide CROSPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes; Clin. Transl. Med. 12 e882

Johansson et al. (2023), Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute Lymphoblastic leukemia; Leukemia 37 2356

Neubauer et al. (2025), Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer; Int. J. Mol. Sci. 26 1078